Biosimilar boom could save billions, think tank claims

Introducing more biosimilars could cut healthcare spending by $54 billion over the next ten years, a figure far higher than initially thought, a think tank and research organisation has claimed.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Conference preview: ACI breaks down Section 337 at the 13th Annual Practitioners’ Think Tank

23 June 2021 Making sense of the newest Section 337 developments will be a key focus of The American Conference Institute’s 13th Annual Practitioners’ Think Tank on ITC Litigation and Enforcement.

Biotechnology

Biosimilars in Italy: a new regime

10 January 2017 Several changes have been made to Italy’s regulatory landscape for biosimilars, as Luca Tosoni of Covington & Burling reports.

Biotechnology

Cutting back the thickets of Biosimilars

1 March 2021 The Biologics market has changed dramatically since the introduction of the Biologics Price Competition and Innovation Act in 2014 in the US. The act provides a pathway for similar biologics to make it to market safely, cost-effectively, and legally.